Crispr, Vertex shares fall after FDA halts sickle-cell disease trial – MarketWatch
|
Crispr, Vertex shares fall after FDA halts sickle-cell disease trial
MarketWatch Crispr Therapeutics CRSP, +6.79% and Vertex Pharmaceuticals Inc. VRTX, +0.90% said late Wednesday the U.S. Food and Drug Administration has put a hold on a new-drug application for a drug used for the treatment of sickle-cell disease, "pending the … |
